FELIQS plans to conduct a Phase 1b/2 study of FLQ-101 (tROPhy-1 study) both in the US and Japan in the first quarter of 2025.

Study points to approach to improving anti-VEGF therapy for all wet AMD patients, and help subset of patients who lose vision ...

Researchers at the Terasaki Institute for Biomedical Innovation (TIBI) have developed a revolutionary injectable granular ...

Researchers at the Terasaki Institute for Biomedical Innovation (TIBI) have developed a revolutionary injectable granular filler that could transform the way diabetic wounds are treated, potentially ...

The Terasaki Institute has created an injectable, porous dermal filler made from biocompatible materials that enhances ...

Researchers have developed a revolutionary injectable granular filler that could transform the way diabetic wounds are treated, potentially improving patient outcomes. The groundbreaking study ...

Biosimilar aflibercept (P041) demonstrated comparable safety and efficacy to the originator aflibercept (Eylea) in treating patients with retinal conditions like neovascular age-related macular ...

Wet AMD is characterized by choroidal neovascularization (CNV). The role of Meteorin-like (Metrnl), an endogenous protein down-regulated in patients and able to ameliorate damage in a photocoagulation ...

What you need to know about smoothing out fine lines, banishing dark circles and prevent ageing. We tell you how.

If you've recently been diagnosed with age-related macular degeneration (AMD), even while you're still processing your diagnosis you're also likely trying to explain AMD to others. But finding the ...